Document is current

Article History

Received: 7 December 2021

Accepted: 4 April 2022

First Online: 25 April 2022

Declarations

:

: The ACHIEVE I and ACHIEVE II trials were conducted in conformance with the Declaration of Helsinki principles, or US laws and regulations, whichever afforded the greater protection to the individual. Trial protocols were approved by each individual research center’s institutional review board. Written informed consent was obtained from all participants prior to initiation of trial procedures. All authors had full access to all data from both studies.

: Not applicable.

: RBL has received research support from the National Institutes of Health, the FDA, and the National Headache Foundation. He serves as consultant, advisory board member, or has received honoraria or research support from AbbVie/Allergan, Amgen, Biohaven, Dr. Reddy’s Laboratories (Promius), electroCore, Eli Lilly, GlaxoSmithKline, Lundbeck, Merck, Novartis, Teva, Vector, and Vedanta Research. He receives royalties from <i>Wolff’s Headache</i>, 8th edition (Oxford University Press, 2009), and Informa. He holds stock/options in Biohaven, Ctrl M, and Manistee.RBHS reports honoraria for advisory boards from Impel, Supernus, and Teva, and grants for research support from Amgen and Eli Lilly.DAR received research support from Allergan and Amgen, and served as a consultant for AbbVie, Allergan, and Amgen.DWD reports the following conflicts: Consulting: Amgen, Atria, Cerecin, Cooltech, Ctrl M, Allergan, Abbvie, Biohaven, GSK, Lundbeck, Eli Lilly, Novartis, Impel, Satsuma, Theranica, WL Gore, Genentech, Nocira, Perfood, Praxis, AYYA Biosciences, Revance. Honoraria: American Academy of Neurology, Headache Cooperative of the Pacific, MF Med Ed Research, Biopharm Communications, CEA Group Holding Company (Clinical Education Alliance LLC), Teva (speaking), Amgen (speaking), Eli Lilly (speaking), Lundbeck (speaking), Vector Psychometric Group, Clinical Care Solutions, CME Outfitters, Curry Rockefeller Group, DeepBench, Global Access Meetings, KLJ Associates, Academy for Continued Healthcare Learning, Majallin LLC, Medlogix Communications, Medica Communications LLC, MJH Lifesciences, Miller Medical Communications, WebMD Health/Medscape, Wolters Kluwer, Oxford University Press, Cambridge University Press. Non-profit board membership: American Brain Foundation, American Migraine Foundation, ONE Neurology, Precon Health Foundation, International Headache Society Global Patient Advocacy Coalition, Atria Health Collaborative, Domestic Violence HOPE Foundation/Panfila. Research Support: Department of Defense, National Institutes of Health, Henry Jackson Foundation, Sperling Foundation, American Migraine Foundation, Patient Centered Outcomes Research Institute (PCORI). Stock Options/Shareholder/Patents/Board of Directors: Ctrl M (options), Aural analytics (options), ExSano (options), Palion (options), Healint (options), Theranica (options), Second Opinion/Mobile Health (options), Epien (options/Board), Nocira (options), Matterhorn (shares/Board), Ontologics (shares/Board), King-Devick Technologies (options/Board), Precon Health (options/Board), AYYA Biosciences (options), Axon Therapeutics (options/Board), Cephalgia Group (options/Board), Atria Health (options/employee). Patent 17189376.1–1466:vTitle: Botulinum Toxin Dosage Regimen for Chronic Migraine Prophylaxis.ARS is an employee of AbbVie, and may hold AbbVie stock.SZ and JEL were employees of AbbVie at the time of study conduct and may hold AbbVie stock.